drugset

drugset / Trial / NCT06203002

A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

NCT06203002 ↗

Phase 2 Completed 496 enrolled Lexicon Pharmaceuticals

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP. Please see study website: https://diabeticpainstudy.com/

Timeline

Start: 2023-11-29
Primary completion: 2025-01-14
Completion: 2025-02-24

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PILAVAPADIN	Small molecule	—	Oral

Indications